| 2025-11-04 |
详情>>
内部人交易：
Sims Andrew John Hugh MacIntyre股份增加20000.00股
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本13742.91万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.29美元,归母净利润-1667.3万美元,同比去年增长-83.72%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.5美元,归母净利润-1225万美元,同比去年增长-97.55%
|
| 2025-07-21 |
股东大会：
将于2025-08-07召开股东大会
会议内容 ▼▲
- 1.Elect six members of our board of directors for a one- year term, to hold office until our Annual Meeting of Stockholders in 2026 and until their successors are duly elected and qualified, or until their earlier death, resignation or removal;
2.Approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance and sale of (i) up to Fifty Million Dollars ($50,000,000) of our common stock, par value $0.001 per share (the “Common Stock”) and (ii) up to One Million Dollars ($1,000,000) of shares of Common Stock (the “Commitment Shares”) as a commitment fee, in each case issuable to Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant to our purchase agreement with Lincoln Park (the “Lincoln Park Purchase Agreement”);
3.Grant discretionary authority to our board of directors to (i) amend our Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to combine outstanding shares of our Common Stock, into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-two hundred fifty (1-for-250), with the exact ratio to be determined by our board of directors in its sole discretion; (ii) effect the reverse stock split, if at all, within twelve months of the date the proposal is approved by stockholders;
4.Provide a non-binding advisory vote on the compensation of our named executive officers;
5.Approve the fifth amendment and restatement of the Company’s 2020 Stock Incentive Plan, the full text of which resolution is set out in the accompanying proxy statement under the heading “Proposal 5- Proposal to Approve the Fifth Amendment and Restatement of the 2020 Stock Incentive Plan;
6.Transact such any other business as may be properly brought before the Annual Meeting.
|
| 2025-05-30 |
详情>>
业绩披露：
2025年一季报每股收益-1.19美元,归母净利润-1740.1万美元,同比去年增长-433.61%
|
| 2025-04-10 |
股东大会：
将于2025-05-02召开股东大会
会议内容 ▼▲
- 1.To grant discretionary authority to our board of directors to (i) amend our Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to combine outstanding shares of our common stock, par value $0.001 per share (the “Common Stock”), into a lesser number of outstanding shares, or a “reverse stock split,” at a specific ratio within a range of one-for-twenty five (1-for-25) to a maximum of a one-for-two hundred fifty (1-for-250), with the exact ratio to be determined by our board of directors in its sole discretion; (ii) effect the reverse stock split, if at all, within twelve months of the date the proposal is approved by stockholders;
2.To authorize, for purposes of complying with Listing Rule 5635(d) of The Nasdaq Stock Market LLC (“Nasdaq”), the issuance of 28,042,138 Series A Warrants (as defined in the accompanying proxy statement) and 28,042,138 Series B Warrants (as defined in the accompanying proxy statement), the issuance of shares of Common Stock that as a result of certain adjustment provisions set forth in the applicable warrants and assumptions described in the accompanying proxy statement could become exercisable for up to 280,421,380 shares of Common Stock in the case of the Series A Warrants and up to 1,261,896,210 shares of Common Stock in the case of the Series B Warrants (in each case subject to the potential for further adjustments), and certain provisions of the Series A Warrants and Series B Warrants, issued in connection with an offering and sale of securities in a private placement of the Company that was consummated on March 4, 2025;
3.To amend the Certificate of Incorporation to increase the authorized shares of Common Stock from 100,000,000 shares to 2,000,000,000 shares;
4.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the extension of the term of the Company’s May 2024 Warrants (as defined in the accompanying proxy statement), issued in connection with the offering and sale of securities in a private placement of the Company that was consummated on May 9, 2024;
5.To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of each of the preceding proposals if there are not sufficient votes at the Special Meeting to approve and adopt the proposals.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-1.95美元,归母净利润-1297.8万美元,同比去年增长2.54%
|
| 2025-03-21 |
复牌提示：
2025-03-20 15:21:42 停牌，复牌日期 2025-03-20 15:26:42
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.46美元,归母净利润-907.5万美元,同比去年增长4.53%
|
| 2024-11-14 |
财报披露：
美东时间 2024-11-14 盘后发布财报
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-1.15美元,归母净利润-620.1万美元,同比去年增长1.37%
|
| 2024-07-10 |
股东大会：
将于2024-08-15召开股东大会
会议内容 ▼▲
- 1.Elect six (6) members of our board of directors for a one- (1) year term, to hold office until our Annual Meeting of Stockholders in 2025 and until their successors are duly elected and qualified, or until their earlier death, resignation or removal;
2.Ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the 2024 fiscal year ending December 31, 2024;
3.Provide a non-binding advisory vote on the compensation of our named executive officers;
4.Approve the fourth amendment and restatement of the Company’s 2020 Stock Incentive Plan, the full text of which resolution is set out in the accompanying proxy statement under the heading “Proposal 4- Proposal to Approve the Fourth Amendment and Restatement of the 2020 Stock Incentive Plan”;
5.Transact such any other business as may be properly brought before the Annual Meeting.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.75美元,归母净利润-326.1万美元,同比去年增长32.13%
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-4.24美元,归母净利润-1331.6万美元,同比去年增长34.32%
|
| 2023-10-31 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.54美元,归母净利润-950.6万美元,同比去年增长34.97%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-2.6美元,归母净利润-628.7万美元,同比去年增长33.10%
|
| 2023-05-01 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2023-03-07 |
股东大会：
将于2023-04-20召开股东大会
会议内容 ▼▲
- 1.Elect members of our board of directors (the “Board”) for a one-year term;
2.Ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2023 fiscal year;
3.Provide a non-binding advisory vote on the compensation of our named executive officers;
4.Provide a non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation;
5.Approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-three (1:3) to one-for-fifteen (1:15);
6.Approve the third amendment and restatement of the Company’s 2020 Stock Incentive Plan;
7.Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2022-04-07 |
股东大会：
将于2022-05-16召开股东大会
会议内容 ▼▲
- 1.elect members of our board of directors (the “Board”) for a one-year term;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2022 fiscal year;
3.approve the issuance of shares of common stock to Lincoln Park pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d);
4.approve the second amendment and restatement of the Company’s 2020 Stock Incentive Plan;
5.provide a non-binding advisory vote on the compensation of our named executive officers;
6.transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-05 |
股东大会：
将于2021-05-17召开股东大会
会议内容 ▼▲
- 1.elect members of our board of directors (the “Board”) for a one-year term;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2021 fiscal year;
3.approve the amendment and restatement of the Company’s 2020 Stock Incentive Plan;
4.provide a non-binding advisory vote on the compensation of our named executive officers;
5.transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2020-05-13 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.elect members of our board of directors (the “Board”) for a one-year term;
2.ratify the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2020 fiscal year;
3.approve the issuance of shares of common stock to Lincoln Park pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d);
4.approve the Plus Therapeutics, Inc. 2020 Equity Incentive Plan;
5.provide a non-binding advisory vote on the compensation of our named executive officers;
6.transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2019-08-06 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2019-04-19 |
股东大会：
将于2019-05-28召开股东大会
会议内容 ▼▲
- 1.Election of members of our Board of Directors for a one-year term;
2.Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2019 fiscal year;
3.Approval of the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan;
4.Approval of an amendment to our amended and restated certificate of incorporation, as amended, to effect, at the discretion of our Board of Directors (with the effectiveness or abandonment of such amendment to be determined by the Board of Directors as permitted under Section 242(c) of the Delaware General Corporation Law) a reverse stock split of our shares of common stock issued and outstanding or reserved for issuance, at an exchange ratio of not less than 1-for-5 and not greater than 1-for-50, such exchange ratio to be determined by our Board of Directors at its sole discretion;
5.Non-binding advisory vote on compensation of our named executive officers;
6.Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2018-05-23 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2018-04-06 |
股东大会：
将于2018-05-18召开股东大会
会议内容 ▼▲
- (1) Election of members of our Board of Directors for a one-year term;
(2) Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2018 fiscal year;
(3) Approval of the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan;
(4) Approval of an amendment to our amended and restated certificate of incorporation, as amended, to effect, at the discretion of our Board of Directors (with the effectiveness or abandonment of such amendment to be determined by the Board of Directors as permitted under Section 242(c) of the Delaware General Corporation Law) a reverse stock split of our shares of common stock issued and outstanding or reserved for issuance, at an exchange ratio of not less than 1-for-5 and not greater than 1-for-15, such exchange ratio to be determined by our Board of Directors at its sole discretion;
(5) Approval of an amendment to our amended and restated certificate of incorporation, as amended, to effect an increase of the total number of authorized shares of common stock under our certificate of incorporation from 75,000,000 shares to 100,000,000 shares (which amount is not otherwise affected by the reverse split);
(6) Non-binding advisory vote on compensation of our named executive officers;
(7) Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2017-04-10 |
股东大会：
将于2017-05-22召开股东大会
会议内容 ▼▲
- (i)Election of members of our Board of Directors for a one-year term;
(ii)Ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the 2017 fiscal year;
(iii)Approval of the amendment and restatement of the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan;
(iv)Non-binding advisory vote on the frequency of holding future non-binding advisory votes on executive officer compensation;
(v)Transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2016-05-10 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2016-03-15 |
股东大会：
将于2016-05-10召开股东大会
会议内容 ▼▲
- 1.Election of members of our Board of Directors for a one-year term;
2.Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the 2016 fiscal year;
3.Approval of an amendment to the Cytori Therapeutics, Inc. 2014 Equity Incentive Plan, to increase the number of shares of common stock reserved for issuance under the Plan by 5,000,000 shares to up to a maximum of 13,502,000 shares (on a pre-split basis);
4.Approval of an amendment to our amended and restated certificate of incorporation, as amended, to effect, at the discretion of our Board of Directors (with the effectiveness or abandonment of such amendment to be determined by the Board of Directors as permitted under Section 242(c) of the Delaware General Corporation Law):
a reverse stock split of our shares of common stock issued and outstanding or reserved for issuance, at an exchange ratio of not less than 1-for-5 and not greater than 1-for-25, such exchange ratio to be determined by our Board of Directors at its sole discretion;if the reverse split is approved by the stockholders, in conjunction with the reverse split a decrease in the total number of authorized shares of common stock under our certificate of incorporation from 290,000,000 shares (which amount is not otherwise affected by the reverse split) to between 25,000,000 and 100,000,000 shares, as determined by our Board of Directors at its sole discretion;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|